Details of Drug-Drug Interaction
| Drug General Information (ID: DDIXK0NET2) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Insulin human (inhalation, rapid acting) | Drug Info | Pramlintide | Drug Info | |||||
| Drug Type | Hormones | Small molecule | |||||||
| Therapeutic Class | Insulin/Antidiabetic Agents | Antidiabetic Agents | |||||||
| Structure | |||||||||
| Mechanism of Insulin human (inhalation, rapid acting)-Pramlintide Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Insulin human (inhalation, rapid acting) | Pramlintide | |||||||
| Mechanism | Hypoglycemic effects | Hypoglycemic effects | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Hypoglycemia | ||||||||
| Factor Description | Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | To reduce the risk of hypoglycemia, it is recommended that mealtime insulin doses be decreased by 50% when initiating pramlintide. Blood glucose should be monitored frequently, including pre- and post-meals and at bedtime, particularly upon initiation of pramlintide therapy and following a dose increase. After the initial 50% reduction in mealtime insulin dose, further adjustments of insulin dose should be individualized based on glycemic control and tolerability of the antidiabetic regimen. An increased frequency of mild-to-moderate hypoglycemia should be viewed as a warning sign of increased risk for severe hypoglycemia. Pramlintide should be discontinued if a patient experiences recurrent unexplained hypoglycemia that requires medical assistance. If pramlintide therapy is temporarily discontinued for any reason (e.g., surgery or illnesses), the same initiation protocol should be followed when therapy is reinstituted. | ||||||||